OncoMatch/Prostate Cancer/BRCA1
Prostate CancerBRCA1 Clinical Trials
BRCA1 alterations occur in approximately 2–3% of prostate cancers and are associated with aggressive disease biology and sensitivity to PARP inhibition. Olaparib and niraparib plus abiraterone are FDA-approved for BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC). Trials investigate PARP inhibitor combinations with AR-directed therapy, lutetium-177 PSMA therapy, and immunotherapy in BRCA1-altered mCRPC.
Top recruiting BRCA1 Prostate Cancer trials
Ranked by phase and US site count. See all 8 trials matched to your profile →
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
AstraZeneca
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Canadian Cancer Trials Group
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
SWOG Cancer Research Network
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Rana McKay, MD
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer Clinical Trials Consortium
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
University of Maryland, Baltimore
Browse other molecular targets with active Prostate Cancer trials.